• SpyGlass Pharma outlined lead BIM-IOL System, designed to deliver at least 3 years of bimatoprost therapy for open-angle glaucoma or ocular hypertension during routine cataract surgery.
• First-in-human feasibility trial showed 95% of patients off topical IOP-lowering drops at 36 months.
• Study also reported 37% mean IOP reduction at 36 months across all doses.
• Phase 1/2 results for intended commercial dose of 78 mcg showed 98% of patients off topical therapy at 12 months.
• Cash, cash equivalents, short-term investments totaled $107.4 million as of Dec. 31, 2025, before $172.5 million gross IPO proceeds closed Feb. 9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.